Urinary Bladder

C67WHO Vol. 8

Urinary Tract

Key facts

New cases per year (US)

84,530 estimated in 2026 — 4.0% of all new cancer cases (SEER)

5-year relative survival

79.1% all stages combined (SEER, 2016–2022)

Main risk factors

Tobacco smoking (major factor); workplace exposure to paints, dyes, metals, petroleum products; arsenic in well water; prior pelvic radiotherapy or cyclophosphamide/ifosfamide; Schistosoma infection (NCI)

Screening and detection

No routine screening test; usually found after blood in urine — urine tests, imaging (e.g. CT urography), cystoscopy with biopsy (NCI)

Typical age and sex

Median age at diagnosis 73; about 4× more common in men (31.0 vs 7.6 per 100,000/yr, SEER)

Urinary bladder cancer arises when cells lining the bladder — the hollow organ in the lower abdomen that stores urine — begin to grow without control. Almost all bladder cancers are urothelial (transitional cell) carcinomas, starting in the cells that line the inside of the bladder; squamous cell carcinoma, adenocarcinoma, and small cell carcinoma are rare. A key distinction for treatment is whether the tumor is confined to the bladder lining (non-muscle-invasive) or has grown into the muscle wall. The most common first sign is blood in the urine (hematuria), often rusty to bright red, which may appear and then disappear for a while; frequent or painful urination can also occur. There is no routine screening test — the disease is usually detected after symptoms prompt urine testing, imaging such as CT urography, and cystoscopy with biopsy, which confirms the diagnosis.

Prognosis

Outlook depends strongly on how far the cancer has spread at diagnosis. In US SEER data (2016–2022), 5-year relative survival is 98.0% for carcinoma in situ (about half of all diagnoses), 73.0% for localized disease, 41.8% for regional spread, and 9.6% for distant metastases; across all stages combined it is 79.1%. Whether the tumor has invaded the bladder's muscle wall, its grade, and the response to treatment also shape the individual outlook. These are population statistics drawn from large groups of past patients — they describe averages, not any one person's future, and individual outcomes vary widely with stage, overall health, and treatment.

🔬 Histological Types

📚 Latest Research

2026-09-09

Risk Stratification in Non-Muscle-Invasive Bladder Cancer in the Era of Expanding Therapeutic Options: Are Current Classifications Still Adequate?

Duquesne I, et al

A narrative review of the four major NMIBC risk classification systems — AFU, EAU, AUA/SUO, and NCCN — concludes that current frameworks remain necessary but are no longer sufficient alone to guide treatment selection in an era of rapidly expanding therapeutic options. The four systems produce discordant risk assignments for identical patients, most sharply for low-burden Ta high-grade disease and T1 disease with concomitant carcinoma in situ, while four agents have received FDA approval for BCG-unresponsive disease and two of three recent phase III trials in BCG-naïve high-risk disease (CREST, POTOMAC) were positive. Real-world adherence to adequate BCG therapy remains below 50%, further complicating eligibility criteria that depend on treatment-exposure definitions outside baseline risk labels. The authors propose a seven-axis, treatment-oriented framework reassessed at defined clinical checkpoints as a more dynamic alternative to fixed diagnosis-time risk labeling.

The French journal of urology

Source →

2026-09-09

Solid tumours in RASopathies: insights from a large monocentric cohort and systematic review of the literature.

Trevisan V, et al

A large monocentric cohort study and systematic literature review found that solid tumour risk in RASopathies is strongly syndrome-dependent, with Costello syndrome (CS) carrying the highest burden: 47.8% of CS individuals developed at least one solid tumour and 30.4% developed malignant tumours, predominantly of the urinary bladder. Among 138 individuals with RASopathies (excluding neurofibromatosis type 1), Noonan syndrome (NS) showed a 10.8% prevalence of solid tumours (5.4% malignant, mainly low-grade CNS tumours linked to PTPN11 variants), while cardiofaciocutaneous syndrome (CFCS) showed 7.3% (2.4% malignant). Median tumour onset occurred at ages 19, 14 and 13 years in NS, CS and CFCS respectively, and candidate high-risk variants in HRAS, PTPN11 and SOS1 were identified that differ from hotspots seen in childhood leukaemia or sporadic cancers. These findings support the development of syndrome-specific and genotype-specific cancer surveillance strategies, particularly bladder cancer monitoring in CS patients.

Journal of medical genetics

Source →

2026-09-09

Quality of life in patients on active surveillance for bladder cancer.

Hurle R, et al

Patients with bladder cancer managed through active surveillance experience measurable impacts on health-related quality of life, underscoring the importance of patient-reported outcomes in this growing management strategy. The study, published in BJU International, evaluated quality-of-life metrics in a cohort of bladder cancer patients enrolled in active surveillance protocols, examining how deferral of immediate treatment affects physical, psychological, and functional well-being. The findings highlight that active surveillance, while sparing patients from immediate procedural burden, carries its own quality-of-life implications that clinicians must address through structured patient support and monitoring. These results are expected to inform shared decision-making discussions between urologists and patients considering surveillance as an alternative to early intervention for low-risk bladder cancer.

BJU international

Source →